{"log_id": 1917890302056276843, "direction": 0, "words_result_num": 51, "words_result": [{"probability": {"variance": 0.01543, "average": 0.905183, "min": 0.587638}, "location": {"width": 1092, "top": 180, "height": 52, "left": 283}, "words": "YP2C19基因强代:型人群单剂量萨注射1C标污的泮托拉唑钠后,约71%的剂量从"}, {"probability": {"variance": 0.023156, "average": 0.924391, "min": 0.401145}, "location": {"width": 919, "top": 221, "height": 43, "left": 214}, "words": "尿中出以及18%通过胆汁泄主粪便出,无托拉唑原型从肾脏排出"}, {"probability": {"variance": 0.000212, "average": 0.984844, "min": 0.970296}, "location": {"width": 59, "top": 258, "height": 32, "left": 214}, "words": "老年"}, {"probability": {"variance": 0.014903, "average": 0.947547, "min": 0.395604}, "location": {"width": 1106, "top": 294, "height": 50, "left": 272}, "words": "老年人(65全76岁)连续静脉给药后,泮托唑的下面积和消除半哀期值与在年轻"}, {"probability": {"variance": 0.003171, "average": 0.979331, "min": 0.74736}, "location": {"width": 747, "top": 333, "height": 43, "left": 214}, "words": "受试者中观察到的相似,因而对老年患者,不建议调整剂量"}, {"probability": {"variance": 7.3e-05, "average": 0.990941, "min": 0.982425}, "location": {"width": 64, "top": 372, "height": 34, "left": 212}, "words": "性别"}, {"probability": {"variance": 0.02053, "average": 0.937301, "min": 0.423909}, "location": {"width": 1108, "top": 409, "height": 52, "left": 272}, "words": "口服给药后,女性中的泮托拉唑纹下面积和血药峰浓较男性有适度增加,但体重调"}, {"probability": {"variance": 0.00863, "average": 0.950576, "min": 0.657521}, "location": {"width": 777, "top": 448, "height": 45, "left": 210}, "words": "整后男性和女性的清除率似,因而没必要歌性别而调整剂量"}, {"probability": {"variance": 8e-06, "average": 0.997377, "min": 0.993692}, "location": {"width": 148, "top": 489, "height": 32, "left": 212}, "words": "肾功能不全"}, {"probability": {"variance": 0.006127, "average": 0.961608, "min": 0.612348}, "location": {"width": 1102, "top": 523, "height": 50, "left": 272}, "words": "严重肾功能不全忌者的泮托拉唑药代动力学参数与正常人类似:别肾功能衰竭患者或血"}, {"probability": {"variance": 0.022452, "average": 0.863193, "min": 0.544413}, "location": {"width": 379, "top": 564, "height": 32, "left": 210}, "words": "液透析的患者,无需词整剂量"}, {"probability": {"variance": 0.023025, "average": 0.921688, "min": 0.618257}, "location": {"width": 150, "top": 603, "height": 32, "left": 210}, "words": "肝与能不全"}, {"probability": {"variance": 0.014155, "average": 0.936246, "min": 0.510688}, "location": {"width": 1111, "top": 637, "height": 52, "left": 267}, "words": "轻度至重度肝切能不全思者(肝硬化患者 child-puph分级A-C)口服泮托拉唑后,最"}, {"probability": {"variance": 0.015499, "average": 0.937813, "min": 0.486029}, "location": {"width": 1163, "top": 676, "height": 50, "left": 210}, "words": "高泮托拉唑浓度相对于正常人仅略有增加(1.5倍》,尽管开脏受损的者的血清半衰期上升"}, {"probability": {"variance": 0.014089, "average": 0.944551, "min": 0.440515}, "location": {"width": 1168, "top": 715, "height": 50, "left": 208}, "words": "到7~9小时,曲线下面积值增打了5~7倍,但这些千幅并未比CYP2C19基因弱气谢且不需"}, {"probability": {"variance": 0.002894, "average": 0.978722, "min": 0.742953}, "location": {"width": 1168, "top": 754, "height": 52, "left": 208}, "words": "调整剂量的人群人,肝脏受损患者的药代动力学变化在每日一次:多剂量给药时,很少导致"}, {"probability": {"variance": 0.021735, "average": 0.919777, "min": 0.410555}, "location": {"width": 1168, "top": 791, "height": 57, "left": 208}, "words": "蓄积,因而轻度至重度肝功能不全忘者无需调整剂,高丁40大的剂量在肝功能受损的患"}, {"probability": {"variance": 0.004252, "average": 0.940684, "min": 0.804681}, "location": {"width": 180, "top": 836, "height": 32, "left": 208}, "words": "者中尚未研究"}, {"probability": {"variance": 0.003909, "average": 0.968349, "min": 0.828769}, "location": {"width": 180, "top": 873, "height": 32, "left": 208}, "words": "药物相互作用"}, {"probability": {"variance": 0.03254, "average": 0.885265, "min": 0.401022}, "location": {"width": 1111, "top": 909, "height": 50, "left": 265}, "words": "泮托拉唑主中CYT2C19:少量由CYPS3A4,2D6和2C9代谢。针Y219底地"}, {"probability": {"variance": 0.03043, "average": 0.887541, "min": 0.363093}, "location": {"width": 1163, "top": 946, "height": 54, "left": 208}, "words": "西绊(CYP3A4的底物)和苯妥英CYP3A秀导剂)]、硝地联唑安定、克拉变"}, {"probability": {"variance": 0.014197, "average": 0.921708, "min": 0.534233}, "location": {"width": 1156, "top": 985, "height": 54, "left": 219}, "words": "(CYP3A4底物)、美托洛尔(CYP2D6底物)、双氯芬酸、恭普生、吡罗苗厦CYP2底"}, {"probability": {"variance": 0.029202, "average": 0.902916, "min": 0.360658}, "location": {"width": 1163, "top": 1024, "height": 52, "left": 205}, "words": "物)和茶残(CYP1A2的底物),在健康受试者中行了体内药物相互作用的研充,泮拉"}, {"probability": {"variance": 0.022009, "average": 0.948814, "min": 0.403654}, "location": {"width": 438, "top": 1067, "height": 36, "left": 205}, "words": "唑的药代动力学性质没有显改变"}, {"probability": {"variance": 0.035674, "average": 0.852163, "min": 0.35878}, "location": {"width": 1108, "top": 1102, "height": 52, "left": 265}, "words": "氨吡格雷部分 CYP2C19代谢成其活性代谢物。在一交叉临末研究中,66位健康受"}, {"probability": {"variance": 0.030501, "average": 0.886233, "min": 0.392682}, "location": {"width": 1166, "top": 1140, "height": 52, "left": 205}, "words": "老给予氯吡格尘(负荷剂为300mg,随后75mg/天)并使用泮托拉唑(8mg,与氯哄格"}, {"probability": {"variance": 0.017347, "average": 0.94009, "min": 0.452912}, "location": {"width": 1163, "top": 1177, "height": 52, "left": 205}, "words": "同时给药),连续5天。第五天时,将氯格雷与泮托泣唑合用时与单独使用氯格进行"}, {"probability": {"variance": 0.012614, "average": 0.949082, "min": 0.445736}, "location": {"width": 1168, "top": 1216, "height": 52, "left": 203}, "words": "比较,氯吡格雷活性代谢产物的平均曲线卜血积减少约14%几何平均比率为86%,90%清"}, {"probability": {"variance": 0.015259, "average": 0.9322, "min": 0.554075}, "location": {"width": 1170, "top": 1252, "height": 52, "left": 203}, "words": "除率时为79%至93%2。药效学参数的测量表明了抑制血小成聚集的改变(由5微摩尔ATP"}, {"probability": {"variance": 0.011531, "average": 0.961565, "min": 0.485956}, "location": {"width": 948, "top": 1291, "height": 48, "left": 203}, "words": "诱导)与氯吡格雷活性代谢产物的变化相关,这一发现的临沐意义尚不清楚"}, {"probability": {"variance": 0.027876, "average": 0.912407, "min": 0.38002}, "location": {"width": 1108, "top": 1328, "height": 54, "left": 262}, "words": "体内研究还表,泮托拉个显著影响其药物的动力学西沙必利、茶碱、地西洋〔和"}, {"probability": {"variance": 0.002948, "average": 0.97228, "min": 0.734773}, "location": {"width": 1168, "top": 1367, "height": 52, "left": 201}, "words": "其活性代谢产物、去甲基地西泮)、华法林、苯妥莫、美托洛尔、硝苯地平、卡马西平、咪"}, {"probability": {"variance": 0.035326, "average": 0.90304, "min": 0.373265}, "location": {"width": 1168, "top": 1403, "height": 57, "left": 201}, "words": "唑安定、克拉霉素、茶普生、吡罗首和口胀避药左炔诺孕炸醇],当它们与唑"}, {"probability": {"variance": 0.035024, "average": 0.867556, "min": 0.406108}, "location": {"width": 1223, "top": 1438, "height": 66, "left": 201}, "words": "联合用药时,没有必要进行剂量调整:在其他内的研究中,地高辛、乙醇、格本"}, {"probability": {"variance": 0.006432, "average": 0.957999, "min": 0.684149}, "location": {"width": 893, "top": 1486, "height": 38, "left": 201}, "words": "替比林、咖啡因、甲硝唑、阿莫西林与托拉唑无临床相关的相互作用"}, {"probability": {"variance": 0.022945, "average": 0.929607, "min": 0.478145}, "location": {"width": 1120, "top": 1515, "height": 59, "left": 253}, "words": "在评估可能与泮托拉唑产生相互作用的究基础上:与下列药物合用时,不需要调整"}, {"probability": {"variance": 0.026728, "average": 0.929364, "min": 0.361413}, "location": {"width": 1175, "top": 1556, "height": 54, "left": 201}, "words": "量:茶礁、四沙必利、安替比林、咖啡因、卡马西平、地西泮(和其活性代谢产物、甲"}, {"probability": {"variance": 0.042354, "average": 0.881755, "min": 0.374784}, "location": {"width": 1170, "top": 1595, "height": 52, "left": 198}, "words": "地西泮),双氯灭痛、地高、秦普、罗昔、乙醇、列本、口服药(左炔诺"}, {"probability": {"variance": 0.002228, "average": 0.985342, "min": 0.714408}, "location": {"width": 1168, "top": 1634, "height": 52, "left": 198}, "words": "孕酮雌醇、雌二醇)、美托洛尔、硝苯地平、苯妥英、法林、咪唑安定、克拉素,甲"}, {"probability": {"variance": 0.030911, "average": 0.831811, "min": 0.498504}, "location": {"width": 208, "top": 1678, "height": 32, "left": 201}, "words": "硝唑、阿莫西"}, {"probability": {"variance": 0.000997, "average": 0.976337, "min": 0.891333}, "location": {"width": 374, "top": 1717, "height": 34, "left": 262}, "words": "与抑酸剂合用时也无相互仁用"}, {"probability": {"variance": 0.015646, "average": 0.931336, "min": 0.561821}, "location": {"width": 1067, "top": 1749, "height": 52, "left": 260}, "words": "上市后告表明思者使用包括注射用泮托拉唑钠并仁随华法林(见【药物工作用】"}, {"probability": {"variance": 0.036629, "average": 0.860339, "min": 0.368501}, "location": {"width": 631, "top": 1787, "height": 43, "left": 201}, "words": "在内的质子条抑制剂,其凝血原时间、IN3升高"}, {"probability": {"variance": 0.011122, "average": 0.952198, "min": 0.541983}, "location": {"width": 1081, "top": 1824, "height": 50, "left": 256}, "words": "虽然在临床研究中未观察到明显的药物相互作用,但对每人多次服用高剂量的泮托拉"}, {"probability": {"variance": 0.014877, "average": 0.94697, "min": 0.478035}, "location": {"width": 720, "top": 1863, "height": 41, "left": 201}, "words": "的弱代谢或肝损伤病人,其潜在的药物相互作用尚未研究"}, {"probability": {"variance": 0, "average": 0.999649, "min": 0.998702}, "location": {"width": 121, "top": 1902, "height": 32, "left": 256}, "words": "其他影响"}, {"probability": {"variance": 0.01968, "average": 0.935135, "min": 0.44606}, "location": {"width": 1113, "top": 1934, "height": 57, "left": 256}, "words": "一项临床药理学研究表明,泮托拉唑每日总剂量口服40mg2周对以下激素的水平天影"}, {"probability": {"variance": 0.023442, "average": 0.886324, "min": 0.488233}, "location": {"width": 1138, "top": 1973, "height": 52, "left": 198}, "words": "响:皮质酵、翠酮、甲状腺素《T2)、甲状腙素CTn),促甲状腺激素、甲腺素结合蛋白"}, {"probability": {"variance": 0.017491, "average": 0.908147, "min": 0.514289}, "location": {"width": 1166, "top": 2014, "height": 48, "left": 201}, "words": "甲状旁腺素、胰岛、胰高血糖东、肾素,醛固酮、促卵泡激素、促黄体激素、催乳激素"}, {"probability": {"variance": 0.045974, "average": 0.78363, "min": 0.471703}, "location": {"width": 146, "top": 2050, "height": 32, "left": 198}, "words": "和兰长激素"}, {"probability": {"variance": 6e-06, "average": 0.998378, "min": 0.993124}, "location": {"width": 178, "top": 2089, "height": 34, "left": 256}, "words": "药物基因组学"}], "language": 3}